

# WellPep Co.,LTD

Category	Enterprise Creation															
○ Corporation (Preliminary Enterprise)	WellPep Co.,LTD															
○ Representative	Kweon Yeong Ik, Kim Jong Min															
○ Establishment year	2018															
○ Specialized Field	New Peptide Drug and Research/Cosmetic Peptide Material															
○ Address	Rm 310, instal, 204 Convensia-daero, Yeonsu-gu, Incheon, Republic of Korea															
○ Home page	- Homepage: www.wellpep.co.kr															
○ Enterprise Brief Introduction	<ul style="list-style-type: none"> <li>-The specialized company in the development of bio-friendly new peptide-drug candidates</li> <li>-Unique module-combined peptide synthesis technology with large manufacturing capacity</li> <li>-Experienced a listed KOSDAQ technology special case</li> </ul>															
○ Product and Pipeline Introduction	<p>[Introduction]</p> <p>Development of market-friendly new peptide drug candidates</p> <ul style="list-style-type: none"> <li>- Development of candidate raw materials for new peptide-derived drugs demanded by customers(Big Pharma)</li> <li>- Planning to expand multiple pipelines with competitive potential (within 1~2/year)</li> <li>- Development of best-in-class and first-in-class materials complying with unmet needs</li> <li>- Strategic goal to licensing out to global big pharma and leading companies</li> </ul> <p>[Development stage]</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="text-align: center;">Technology application</th> <th style="text-align: center;">Development stage</th> <th style="text-align: center;">Detailed description</th> </tr> </thead> <tbody> <tr> <td>Multidrug-resistant antimicrobial peptide drug</td> <td>Candidate substance screening (Safety, efficacy study: in vitro)</td> <td>Joint study (Incheon Univ/KBSI)</td> </tr> <tr> <td>Alzheimer's disease Inhibitor</td> <td>Candidate substance screening (Safety, efficacy study: in vitro)</td> <td>Joint study (Aju Univ.)</td> </tr> </tbody> </table>	Technology application	Development stage	Detailed description	Multidrug-resistant antimicrobial peptide drug	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Incheon Univ/KBSI)	Alzheimer's disease Inhibitor	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Aju Univ.)						
Technology application	Development stage	Detailed description														
Multidrug-resistant antimicrobial peptide drug	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Incheon Univ/KBSI)														
Alzheimer's disease Inhibitor	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Aju Univ.)														
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<ul style="list-style-type: none"> <li>- 7 Patent application (Application number: PCT/KR2019/013926, 10-2019-0174349, 10-2020-0056056, 10-2020-0086609, 10-2020-0162592, 10-2020-0162593, 10-2020-0175373)</li> <li>- 3 Patent registered (Patent number: 10-1381285, 10-2146006, 10-2177642)</li> <li>- Certified Venture Business and, ISO-9001/14001</li> <li>- Current Investment attraction status</li> </ul> <p style="text-align: right;">(Unit: KRW 1,000)</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="text-align: center;">Investment destination</th> <th style="text-align: center;">Amount</th> <th style="text-align: center;">Stock</th> </tr> </thead> <tbody> <tr> <td>SID partners No.2 Angel Fund</td> <td style="text-align: center;">22,500</td> <td style="text-align: center;">13,000</td> </tr> <tr> <td>Big Bang Angels Investment association No.14</td> <td style="text-align: center;">100,000</td> <td style="text-align: center;">59,180</td> </tr> <tr> <td>Incheon Intellectual Property No. 2 Investment association</td> <td style="text-align: center;">100,000</td> <td style="text-align: center;">51,000</td> </tr> <tr> <td style="text-align: center;">계</td> <td style="text-align: center;">222,500</td> <td style="text-align: center;">123,180</td> </tr> </tbody> </table>	Investment destination	Amount	Stock	SID partners No.2 Angel Fund	22,500	13,000	Big Bang Angels Investment association No.14	100,000	59,180	Incheon Intellectual Property No. 2 Investment association	100,000	51,000	계	222,500	123,180
Investment destination	Amount	Stock														
SID partners No.2 Angel Fund	22,500	13,000														
Big Bang Angels Investment association No.14	100,000	59,180														
Incheon Intellectual Property No. 2 Investment association	100,000	51,000														
계	222,500	123,180														